• Chloroquine: Applied Autophagy Inhibition for Research Workf

  2026-05-09

  Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) empowers cellular pathway interrogation in malaria and rheumatoid arthritis research, as well as novel pathogen studies. This guide delivers actionable protocols, troubleshooting strategies, and experimental insights enabled by high-purity Chloroquine from APExBIO.

• Losmapimod (GW856553X): Next-Generation Precision in Inflamm

  2026-05-08

  Explore how Losmapimod (GW856553X) sets a new standard for precision inflammation signaling modulation and vascular function research. This article uniquely dissects conformational selectivity and dual-action inhibition, offering deep mechanistic insights for advanced assay design.

• RSL3 and the Future of Ferroptosis: Strategy for Translation

  2026-05-08

  Explore how (1S,3R)-RSL3, a selective glutathione peroxidase 4 inhibitor, is transforming ferroptosis research and translational cancer biology. This article integrates mechanistic insights, protocol guidance, and competitive context, highlighting RSL3’s role in exploiting synthetic lethality in oncogenic RAS-driven tumors and its implications for therapy-resistant malignancies.

• SCH772984 HCl: Potent ERK1/2 Inhibitor for MAPK Pathway Rese

  2026-05-07

  SCH772984 HCl is a highly selective ERK1/2 inhibitor with nanomolar potency, enabling mechanistic MAPK pathway studies and resistance modeling in BRAF- and RAS-mutant cancer. Its robust in vitro and in vivo benchmarks make it a reference compound for translational oncology research.

• Tubastatin A: A Selective HDAC6 Inhibitor for Translational

  2026-05-07

  Tubastatin A stands out as a highly selective HDAC6 inhibitor, enabling precision in targeting epigenetic and cytoskeletal pathways. Its robust performance in myocardial protection, cancer biology, and inflammation research makes it indispensable for advanced experimental workflows.

• ECM1 Drives Anti-Androgen Resistance in Bone Metastatic Pros

  2026-05-06

  This study elucidates how osteoblast-derived ECM1 promotes resistance to anti-androgen therapies in bone metastatic prostate cancer by activating MAPK signaling via ENO1. The findings highlight ECM1 and ENO1 as actionable targets for overcoming hormonal therapy resistance, shaping future research on castration-resistant disease.

• Tubastatin A in Translational Cardiac and Neuroprotection Re

  2026-05-06

  Explore how Tubastatin A, a selective HDAC6 inhibitor, uniquely advances translational research in cardiac injury and neuroprotection. This article offers actionable protocol insights and contextualizes the latest experimental breakthroughs.

• RSL3 Glutathione Peroxidase 4 Inhibitor: Optimizing Ferropto

  2026-05-05

  RSL3, a potent glutathione peroxidase 4 inhibitor, empowers cancer researchers to induce and dissect ferroptosis with unprecedented selectivity and reproducibility. Streamline your workflow with protocol enhancements, troubleshooting insights, and actionable lessons from recent breakthroughs in cell death signaling.

• Cy5 NHS ester(Et): Workflow Guidance for Fluorescent Labelin

  2026-05-05

  Cy5 NHS ester(Et) enables efficient, water-soluble fluorescent labeling of primary amines in proteins and biomolecules, supporting applications like immunofluorescence staining, flow cytometry, and microscopy. It should not be used with ethanol-based protocols or for long-term storage of dye solutions, and immediate use after preparation is recommended for optimal results.

• TMEM16F Lipid Scrambling Regulates Ferroptosis and Tumor Imm

  2026-05-04

  Yang et al. reveal TMEM16F as a key suppressor of ferroptosis execution via plasma membrane lipid scrambling. Their findings highlight that disrupting this process not only sensitizes cancer cells to ferroptosis but also enhances tumor immune rejection, suggesting new avenues for combinatorial cancer therapy.

• CUDC-907: Protocol Guidance for Dual PI3K and HDAC Inhibitio

  2026-05-04

  CUDC-907 is a research-only dual PI3K and HDAC inhibitor designed for controlled in vitro studies of cancer cell signaling, cell cycle arrest, and apoptosis. It is not suitable for diagnostic, therapeutic, or clinical applications and should only be used according to validated laboratory protocols.

• HDAC Inhibition Reverses EBV-Induced Plasticity in NPC Cells

  2026-05-03

  This study uncovers the mechanism by which Epstein-Barr virus (EBV) drives dedifferentiation and plasticity in nasopharyngeal carcinoma (NPC) via histone deacetylase (HDAC)-mediated repression of CEBPA. The findings demonstrate that HDAC inhibition can restore differentiation in NPC models, highlighting a promising epigenetic strategy for targeting solid tumor plasticity.

• Tubastatin A Mitigates Cardiac Injury via Pyroptosis and Nec

  2026-05-02

  The referenced study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, significantly reduces myocardial damage following cardiac arrest in a porcine model by suppressing GSDME-mediated pyroptosis and MLKL-mediated necroptosis. These findings provide mechanistic insight into how HDAC6 inhibition could be leveraged for organ protection in ischemia-reperfusion injury.

• Targeting Palmitoylation: Next-Gen Strategies in Cancer Rese

  2026-05-01

  This thought-leadership article explores the mechanistic role of protein S-palmitoylation—particularly via DHHC9-mediated STRN4 palmitoylation—in driving cancer metastasis through Hippo pathway dysregulation. It provides translational researchers with strategic guidance on leveraging the DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) for high-throughput screening of anti-cancer agents, enabling discovery of novel pathway modulators such as BRAF kinase inhibitors. Integrating recent research advances and highlighting competitive advantages, the article bridges mechanistic insight with practical recommendations and protocol parameters, positioning APExBIO's L1023 as a premier tool for next-generation oncology discovery.

• PD0325901: MEK Inhibitor Workflows for Tumor Suppression

  2026-05-01

  PD0325901, a selective MEK inhibitor from APExBIO, enables precise control of the RAS/RAF/MEK/ERK pathway for robust tumor growth suppression and apoptosis induction in cancer research. This article dissects actionable protocols, troubleshooting strategies, and experimental advantages, including cross-validation with recent stem cell fate studies.

15599 records 1/1040 page Next 12345 下5页 Last page